124 related articles for article (PubMed ID: 36503469)
41. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.
Uckun FM; Herman-Hatten K; Crotty ML; Sensel MG; Sather HN; Tuel-Ahlgren L; Sarquis MB; Bostrom B; Nachman JB; Steinherz PG; Gaynon PS; Heerema N
Blood; 1998 Aug; 92(3):810-21. PubMed ID: 9680349
[TBL] [Abstract][Full Text] [Related]
42. Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City.
Daniel-Cravioto A; Gonzalez-Bonilla CR; Mejia-Arangure JM; Perez-Saldivar ML; Fajardo-Gutierrez A; Jimenez-Hernandez E; Hernandez-Serrano M; Bekker-Mendez VC
Leuk Lymphoma; 2009 Aug; 50(8):1352-60. PubMed ID: 19579075
[TBL] [Abstract][Full Text] [Related]
43. Molecular analysis of MLL-1/AF4 recombination in infant acute lymphoblastic leukemia.
Borkhardt A; Repp R; Haupt E; Brettreich S; Buchen U; Gossen R; Lampert F
Leukemia; 1994 Apr; 8(4):549-53. PubMed ID: 8152249
[TBL] [Abstract][Full Text] [Related]
44. Cryptic splice site activation during RNA processing of MLL/AF4 chimeric transcripts in infants with t(4;11) positive ALL.
Divoky V; Trka JM; Watzinger F; Lion T
Gene; 2000 Apr; 247(1-2):111-8. PubMed ID: 10773450
[TBL] [Abstract][Full Text] [Related]
45. Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.
Ikawa Y; Sugimoto N; Koizumi S; Yachie A; Saikawa Y
J Pediatr Hematol Oncol; 2010 Jan; 32(1):4-10. PubMed ID: 20051780
[TBL] [Abstract][Full Text] [Related]
46. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs.
Bueno C; Ayllón V; Montes R; Navarro-Montero O; Ramos-Mejia V; Real PJ; Romero-Moya D; Araúzo-Bravo MJ; Menendez P
Blood; 2013 May; 121(19):3867-78, S1-3. PubMed ID: 23479570
[TBL] [Abstract][Full Text] [Related]
47. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH
Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771
[TBL] [Abstract][Full Text] [Related]
48. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
49. MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.
Godfrey L; Kerry J; Thorne R; Repapi E; Davies JO; Tapia M; Ballabio E; Hughes JR; Geng H; Konopleva M; Milne TA
Exp Hematol; 2017 Mar; 47():64-75. PubMed ID: 27856324
[TBL] [Abstract][Full Text] [Related]
50. Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.
Matkar S; Katona BW; Hua X
Cancer Cell; 2014 Apr; 25(4):411-3. PubMed ID: 24735921
[TBL] [Abstract][Full Text] [Related]
51. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.
Lin S; Luo RT; Shrestha M; Thirman MJ; Mulloy JC
Blood; 2017 Aug; 130(7):903-907. PubMed ID: 28637661
[TBL] [Abstract][Full Text] [Related]
52. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
53. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Liu H; Westergard TD; Cashen A; Piwnica-Worms DR; Kunkle L; Vij R; Pham CG; DiPersio J; Cheng EH; Hsieh JJ
Cancer Cell; 2014 Apr; 25(4):530-42. PubMed ID: 24735925
[TBL] [Abstract][Full Text] [Related]
54. Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein.
Caslini C; Serna A; Rossi V; Introna M; Biondi A
Leukemia; 2004 Jun; 18(6):1064-71. PubMed ID: 14990976
[TBL] [Abstract][Full Text] [Related]
55. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
[TBL] [Abstract][Full Text] [Related]
56. Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review).
Organista-Nava J; Gómez-Gómez Y; Illades-Aguiar B; Leyva-Vázquez MA
Oncol Rep; 2016 Sep; 36(3):1226-32. PubMed ID: 27431573
[TBL] [Abstract][Full Text] [Related]
57. The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.
Sun YN; Hu YX; Gao L; Xiao PF; Lu J; Wu SY; Wang M; Shao XJ; Zhou CY; Ling J; Li JQ; Pan J; Gao J; Hu SY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6020-6029. PubMed ID: 30280786
[TBL] [Abstract][Full Text] [Related]
58. Cryptic t(4;11) encoding MLL-AF4 due to insertion of 5' MLL sequences in chromosome 4.
von Bergh A; Gargallo P; De Prijck B; Vranckx H; Marschalek R; Larripa I; Kluin P; Schuuring E; Hagemeijer A
Leukemia; 2001 Apr; 15(4):595-600. PubMed ID: 11368362
[TBL] [Abstract][Full Text] [Related]
59. [Detection of fusion genes resulting from chromosome abnormalities in childhood acute lymphoblastic leukemia].
He J; Chen ZX; Xue YQ; Li JQ; He HL; Huang YP; He YX; Chai YH; Zhu LL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Oct; 22(5):551-3. PubMed ID: 16215946
[TBL] [Abstract][Full Text] [Related]
60. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
